Table II.

Preclinical and Clinical Therapeutics Targeting Caspases and Its Modulators

Companies: Aventis (www.aventis.com), Idun Pharmaceuticals, Inc. (www.idun.com), Maxim Pharmaceuticals (www.maxim.com), Merck Frosst Canada & Co. (www.merck-frosst.ca), Vertex pharmaceuticals, Inc. (www.vpharm.com), Eli Lilly and Company (www.lilly.com), NCI (National Cancer Institute, www.cancer.gov), NCI of Canada (National Cancer Institute of Canada www.ncic.cancer.ca); Ascenta Therapeutics (www.ascenta.com); Aegera Therapeutics Inc. (www.aegera.com), Hybridon (www.hybridon.com); Genta Incorporated (www.genta.com); Kyowa Hakko Kogyo Co., Ltd (www.kyowa.co.jp); ISIS Pharmaceuticals (www.isispharm.com); Hybridon (www.hybridon.com).